wr-142-490 and Parkinsonian-Disorders

wr-142-490 has been researched along with Parkinsonian-Disorders* in 1 studies

Other Studies

1 other study(ies) available for wr-142-490 and Parkinsonian-Disorders

Article	Year
Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorganic & medicinal chemistry letters, 2008, May-01, Volume: 18, Issue:9 The (-)-(11R,2'S)-enantiomer of the antimalarial drug mefloquine has been found to be a reasonably potent and moderately selective adenosine A(2A) receptor antagonist. Further investigation of this compound has led to the discovery of a series of keto-aryl thieno[3,2-d]pyrimidine derivatives, which are potent and selective antagonists of the adenosine A(2A) receptor. These derivatives show selectivity against the A(1) receptor. Furthermore, some of these compounds have been shown to have in vivo activity in a commonly used model, suggesting the potential for the treatment of Parkinson's disease. Topics: Adenosine A2 Receptor Antagonists; Antimalarials; Antiparkinson Agents; Humans; Models, Chemical; Parkinsonian Disorders; Pyrimidines; Stereoisomerism; Structure-Activity Relationship	2008

Article

Year

Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.

Bioorganic & medicinal chemistry letters, 2008, May-01, Volume: 18, Issue:9

The (-)-(11R,2'S)-enantiomer of the antimalarial drug mefloquine has been found to be a reasonably potent and moderately selective adenosine A(2A) receptor antagonist. Further investigation of this compound has led to the discovery of a series of keto-aryl thieno[3,2-d]pyrimidine derivatives, which are potent and selective antagonists of the adenosine A(2A) receptor. These derivatives show selectivity against the A(1) receptor. Furthermore, some of these compounds have been shown to have in vivo activity in a commonly used model, suggesting the potential for the treatment of Parkinson's disease.

Topics: Adenosine A2 Receptor Antagonists; Antimalarials; Antiparkinson Agents; Humans; Models, Chemical; Parkinsonian Disorders; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2008